Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00374751 · ClinicalTrials.gov registry record · Phase 1

Effect of Samarium on the Relief of Pain Due to Vertebral Metastases

A Phase 1 study of Cancer and Pain, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
1
Study location

NCT00374751: Completed Phase 1 study of Cancer and Pain, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

NCT00374751 is a Phase 1 study of Cancer and Pain that has completed, run by New York Presbyterian Brooklyn Methodist Hospital. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00374751, a Phase 1 study of Cancer and Pain, has completed, sponsored by New York Presbyterian Brooklyn Methodist Hospital.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance. The investigators are studying the effects (good or bad) of adding samarium (a radioactive substance) to the cement that is injected into the induced cavity.

Primary Outcome

Measuring the pain by the Visual Analogue Scale

Interventions

  • DRUG Samarium (153SM)

Study Locations (1)

New York

  • New York Methodist Hospital - Brooklyn

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2006-05
Est. Completion 2016-01
Phase Phase 1

What the finished NCT00374751 record still lists

NCT00374751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Samarium (153SM) is the first listed.

NCT00374751 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00374751 about?

NCT00374751 is a clinical study titled "Effect of Samarium on the Relief of Pain Due to Vertebral Metastases". Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance. The investigators are studying the effects (good or bad) o...

What is the current status of trial NCT00374751?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-05. Estimated completion is 2016-01.

What conditions does trial NCT00374751 study?

This clinical trial studies the following conditions: Cancer, Pain, Metastasis.

What interventions are being tested in trial NCT00374751?

The interventions under investigation include: Samarium (153SM) (DRUG).

Who is sponsoring clinical trial NCT00374751?

This trial is sponsored by New York Presbyterian Brooklyn Methodist Hospital, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00374751 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00374751's enrollment target sits among peer trials

29 524th of 615 higher than 89 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00374751, the US trial registry maintained by the National Library of Medicine. NCT00374751 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.